- Solid Tumors
- Pipeline Molecules
- Alliance Partners
Our mission is to provide healthcare professionals with unbiased clinical research information, easily.
Currently, you can access the following clinical trials being conducted worldwide:
CD19 is a surface glycoprotein belonging to the immunoglobulin (Ig) superfamily that can act as a central positive response regulator in B cells.1-3 CD19 is expressed during normal B-cell development, and the expression is maintained following malignant transformation of B cells.2-4 The specific expression of CD19 in B-cell lineage lymphomas and leukemias makes CD19 a promising target antigen in B-cell malignancies, like non-Hodgkin lymphomas, through investigational therapies such as chimeric antigen receptor (CAR) T cell therapy.2-4